An interventional study of Continuous Renal Replacement Therapy (CRRT) in Acute Kidney Injury and Dialysis; Complications, sponsored by University of Alberta. Recruiting at 10 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by University of Alberta · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 83 studies in Acute Kidney Injury with a site in Canada — 19 open to participants now, 22 under way, 1 of them phase 3. Acute Kidney Injury · Canada.
Among the 83 studies in Acute Kidney Injury with a site in Canada, this one is the 31st largest by planned enrollment of the 54 interventional ones that give a count, is one of 7 that started in 2024, is one of 21 with no phase, reaches primary completion later than 5 of the 21 other live ones, and was the 71st registered.
1,693 studies on the registry are indexed under Acute Kidney Injury; 392 are open to participants now.
Browse Acute Kidney Injury studies →19 of the 83 studies in Acute Kidney Injury with a site in Canada are open now. Recruiting first, the newest first:
Uppsala University · Sites in Canada, Australia, Brazil and 7 more countries
Ages 0–16
AstraZeneca · Sites in Canada, United States, Argentina and 11 more countries
Ages 18–80
Matthew James · Sites in Canada
Ages 18+
Hamilton Health Sciences Corporation · Sites in Canada
Ages 18+
University of California, San Francisco · Sites in Canada, United States
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 229 Acute Kidney Injury studies recruiting now, 161 (70%) set no upper age limit and 35 (15%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
83 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 18 · Phase 3 9 · Phase 4 6
First in 1996; this study’s year is marked. 7 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is close to the median of 100 across 819 interventional studies indexed under Acute Kidney Injury.
Median enrollment 137 across the 54 interventional studies, 500 across the 29 observational. Of the 52 that completed or were terminated, 10 (19%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 83 have an industry lead sponsor. The 10 most frequent:
University of Alberta is the lead sponsor of 825 studies on the registry; 172 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.
University of Alberta has 9 studies filed under Acute Kidney Injury — fewer than ten, so there is no comparison to draw.
10 of the studies in Acute Kidney Injury with a site in Canada that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06337838Phase 3Hamilton Health Sciences CorporationBleeding Reduction in Acute and Chronic Kidney Patients Having Surgery (BRACKETS) Pilot Trial | 2027-02 |
| NCT06446739University of AlbertaLoW Dose-Intensity vs. Standard Dose-Intensity COntinuous Renal ReplaceMent Therapy in Critically Ill Patients (WISDOM) | 2026-12 |
| NCT06823115Indiana UniversityAssessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0 | 2027-01 |
| NCT04936607Montreal Heart InstituteImproviNg rEnal Outcomes Following Coronary angiograPhy and/or percuTaneoUs coroNary intErventions | 2027-01-30 |
| NCT07215702AstraZenecaA Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury. | 2027-02-11 |
Add all 10 to your calendar (.ics) → With an account.
Among the 83 studies in Acute Kidney Injury with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
An estimated 10-15% of critically ill patients with acute kidney failure in the intensive care unit receive acute dialysis therapy. The majority of these patients initially receive a continuous form of dialysis therapy call continuous renal replacement therapy (CRRT). Prior studies have suggested that higher CRRT dose-intensity improved health outcomes for these patients; however, this was not found in high-quality clinical trials. These more recent trials suggested a lower range of dose-intensity compared with the higher range as the new standard of care. This was incorporated into guidelines. To date, no clinical trials have evaluated this lower range and specifically, it is plausible that an even lower dose-intensity of CRRT may be well tolerated, safe, associated with similar outcomes and be more cost-effective. This is the objective of the WISDOM trial, to compare the guideline standard with lower dose-intensity among patients who are started on CRRT in the intensive care unit.
Purpose: To primarily determine whether a lower CRRT dose-intensity in critically ill patients with acute kidney injury (AKI) is non-inferior to standard CRRT dose-intensity and to secondarily determined whether lower CRRT dose intensity will shorten total CRRT duration and improve kidney recovery compared with standard CRRT dose-intensity.
Hypothesis: The primary hypothesis of the WISDOM trial is that lower CRRT dose-intensity is non-inferior to current standard guideline-directed CRRT dose-intensity for critically ill patients with AKI with respect to duration of CRRT and successful liberation from RRT and kidney recovery. The secondary hypothesis of the WISDOM trial is that lower dose-intensity is superior to current standard guideline-directed CRRT dose-intensity for critically ill patients with AKI with respect to duration of CRRT and successful liberation from RRT and kidney recovery.
Justification: No randomized controlled trial (RCT) to date has specifically evaluated the lower dose-intensity threshold for critically ill patients receiving CRRT. Specifically, there has been no specific evidence or guidance on the minimum dose-intensity targets for patients receiving CRRT. This is important for several reasons. First, CRRT is an invasive, resource intensive and expensive therapy. As such, there should be a concerted effort to minimize time on RRT and facilitate early recovery and weaning. Second, abundant evidence derived from secondary analyses have suggested that higher CRRT dose-intensity can propagate oliguria, prolong CRRT therapy and delay kidney recovery. This would imply that lower dose-intensity may facilitate kidney recovery and earlier weaning from CRRT. Third, there may be added implications of higher dose-intensity, including prolongation of non-renal organ support, such as delay in weaning from invasive mechanical ventilation. Fourth, evidence derived from observational registries show that lower CRRT dose-intensity, in the range proposed in this trial, provides comparable efficacy in azotemic, metabolic and acid-base homeostasis with similar outcomes. Observational data have suggested a prescribed CRRT dose-intensity of 15 mL/kg/hr may be sufficient for metabolic and azotemic control and is not associated with worse outcomes compared with guideline directed dose-intensity. This is lower quality evidence, however, implies that lower dose-intensity may be acceptable and safe. Fifth, it is plausible that following a short period of metabolic stabilization with CRRT, the minimum recommended CRRT dose-intensity of 20-25 mL/kg/hr may be excessive and have unmeasurable harm (e.g., excessive clearance of electrolytes, micronutrients, and medications [antimicrobials]). Finally, the prescription of a lower CRRT dose-intensity may have meaningful impact on reducing bedside nursing workload (e.g., fewer replacement solution bag changes) and reducing costs attributable to CRRT (e.g., lower effluent rates will reduce total replacement solution utilized).
While this proposal outlines a pilot feasibility trial, it is aimed at performing a larger rigorous RCT that will generate generalizable and high-quality evidence to impact clinical practice. The findings of the main phase of the WISDOM trial will provide clearer evidence to guide the prescription of a minimal dose-intensity for patients receiving CRRT. While this may be an effluent dose of 20-25 mL/kg/hr, it is entirely plausible that this will be a lower dose-intensity.
Objectives: The overall WISDOM trial program will address whether a lower CRRT dose-intensity in critically ill patients with AKI is non-inferior to standard CRRT dose-intensity and will secondarily address whether lower CRRT dose intensity will shorten total CRRT duration and improve kidney recovery compared with standard CRRT dose-intensity.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The intervention arm will consist of low dose-intensity CRRT, defined as the hourly delivery of a total effluent of 10-15 mL/kg/hr while receiving CRRT. The intervention dose-intensity is based on the rationale that 10-15 mL/kg/hr is the lower threshold of dose-intensity currently provided in clinical practice and prior observational data showing this threshold is tolerated and safe.
Device: Continuous Renal Replacement Therapy (CRRT)
The control arm will receive a dose-intensity CRRT of 25-30 mL/kg/hr while receiving CRRT, aligned with local practice and information by international clinical practice guidelines. The control dose-intensity is based on the rationale that this is currently recommended in clinical practice guidelines and is commonly applied in routine practice.
Device: Continuous Renal Replacement Therapy (CRRT)
Continuous Renal Replacement Therapy (CRRT) is a continuous form of acute renal replacement (hemofiltration/dialysis) therapy provided to critically ill patients with multi-organ dysfunction receiving life support in the intensive care unit (ICU).
Difference in delivered CRRT dose-intensity
This pilot trial will target detection of a minimum difference of 10 mL/kg/hr in delivered dose-intensity.
Time frame: Through study completion, an average of 1 month.
Feasibility - consent rate
Consent rate for participation by patient or surrogate decision-maker (SDM).
Time frame: Through study completion, at 90-days.
Feasibility - time to enrollment
Time from eligibility (e.g., starting RRT) to randomization.
Time frame: During active recruitment into the trial, approximately 1 year.
Feasibility - adherence to prescribed CRRT dose-intensity
Protocol adherence for allocated CRRT dose-intensity.
Time frame: Through study completion, at 90-days.
Feasibility - ascertainment to delivered CRRT process measures
Ability to capture delivered CRRT dose-intensity measures.
Time frame: Through study completion, at 90-days.
Feasibility - outcome ascertainment
Ability to capture patient and kidney endpoints at 90-days.
Time frame: Through study completion, at 90-days.
Feasibility - recruitment rate
Ability to recruit 2 patients per site per month.
Time frame: During active recruitment into the trial, approximately 1 year.
Daily bicarbonate while receiving CRRT, an average of 1 month.
Physiological and biochemical outcomes.
Time frame: Through study completion, at 90-days.
Daily serum phosphate while receiving CRRT, an average of 1 month
Physiological and biochemical outcomes.
Time frame: Through study completion, at 90-days.
Daily serum urea while receiving CRRT, an average of 1 month
Physiological and biochemical outcomes.
Time frame: Through study completion, at 90-days.
The total treatment time per day while receiving CRRT following randomization.
Process of care measures.
Time frame: Through study completion, at 90-days.
The total number of hemofilter/circuit replacements while receiving CRRT following randomization.
Process of care measures.
Time frame: Through study completion, at 90-days.
The lowest and highest CRRT dose-intensity delivered for any given hour following randomization.
Process of care measures.
Time frame: While receiving CRRT, an average of 1 month.
The proportion of hours of CRRT when the dose-intensity is in the target range following randomization.
Process of care measures.
Time frame: Through study completion, at 90-days.
Occurrence of adverse and serious adverse events.
Safety measures.
Time frame: Through study completion, at 90-days.
Occurrence of adverse events and serious adverse events leading to discontinuation of the trial intervention.
Safety measures.
Time frame: Through study completion, at 90-days.
RRT-free days at 90-days.
Clinical Outcomes.
Time frame: Through study completion, at 90-days.
The total volume of replacement/dialysate fluid used per day following randomization.
Process of care measures
Time frame: Through study completion, at 90-days.
The total number of doses of supplemental electrolytes administered while receiving CRRT following randomization.
Process of care measures
Time frame: Through study completion, at 90 days.
The cumulative doses of supplemental electrolytes administered while receiving CRRT following randomization.
Process of care measures
Time frame: Through study completion, at 90 days.
The mean daily net ultrafiltration delivery while receiving CRRT following randomization.
Process of care measures
Time frame: Through study completion, at 90 days.
Started Nov 2024 (actual). Primary completion is estimated for Dec 2026, 25 months after the start.
Of 251 non-industry interventional studies with no phase under Acute Kidney Injury, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 44. This study's planned 25 months is close to that.
Counting every sponsor, half of 269 studies reached it within 26 months; a quarter within 12 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.